12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

OxOnc Development Services, Pfizer deal

Pfizer partnered with oncology development company OxOnc to conduct an Asian pivotal trial to evaluate Pfizer's Xalkori crizotinib to treat patients with advanced non-small cell lung cancer (NSCLC) with c-ros...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >